Eupraxia Pharmac Financials
This page shows Eupraxia Pharmac (EPRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Eupraxia Pharmac passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Eupraxia Pharmac generates $0.73 in operating cash flow (-$20.7M OCF vs -$28.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Eupraxia Pharmac generated $0 in revenue in fiscal year 2023.
Eupraxia Pharmac reported -$28.2M in net income in fiscal year 2023. This represents a decrease of 52.6% from the prior year.
Eupraxia Pharmac earned $-1.17 per diluted share (EPS) in fiscal year 2023. This represents a decrease of 21.9% from the prior year.
Eupraxia Pharmac held $19.3M in cash against $0 in long-term debt as of fiscal year 2023.
Eupraxia Pharmac had 27M shares outstanding in fiscal year 2023. This represents an increase of 26.3% from the prior year.
Eupraxia Pharmac invested $20.6M in research and development in fiscal year 2023. This represents an increase of 50.9% from the prior year.
EPRX Income Statement
| Metric | Q4'23 | Q4'22 |
|---|---|---|
| Revenue | N/A | N/A |
| Cost of Revenue | N/A | N/A |
| Gross Profit | N/A | N/A |
| R&D Expenses | N/A | N/A |
| SG&A Expenses | N/A | N/A |
| Operating Income | N/A | N/A |
| Interest Expense | N/A | N/A |
| Income Tax | N/A | N/A |
| Net Income | N/A | N/A |
| EPS (Diluted) | N/A | N/A |
EPRX Balance Sheet
| Metric | Q4'23 | Q4'22 |
|---|---|---|
| Total Assets | $20.3M+6.0% | $19.1M |
| Current Assets | $19.8M+6.5% | $18.6M |
| Cash & Equivalents | $19.3M+5.9% | $18.3M |
| Inventory | N/A | N/A |
| Accounts Receivable | N/A | N/A |
| Goodwill | N/A | N/A |
| Total Liabilities | $19.4M+62.6% | $11.9M |
| Current Liabilities | $19.4M+533.5% | $3.1M |
| Long-Term Debt | N/A | N/A |
| Total Equity | $2.2M-71.5% | $7.8M |
| Retained Earnings | -$105.5M-36.5% | -$77.3M |
EPRX Cash Flow Statement
| Metric | Q4'23 | Q4'22 |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Investing Cash Flow | N/A | N/A |
| Financing Cash Flow | N/A | N/A |
| Dividends Paid | N/A | N/A |
| Share Buybacks | N/A | N/A |
EPRX Financial Ratios
| Metric | Q4'23 | Q4'22 |
|---|---|---|
| Gross Margin | N/A | N/A |
| Operating Margin | N/A | N/A |
| Net Margin | N/A | N/A |
| Return on Equity | N/A | N/A |
| Return on Assets | N/A | N/A |
| Current Ratio | 1.02-5.1 | 6.08 |
| Debt-to-Equity | 8.74+7.2 | 1.53 |
| FCF Margin | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Eupraxia Pharmac's annual revenue?
Eupraxia Pharmac (EPRX) reported $0 in total revenue for fiscal year 2023. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Eupraxia Pharmac profitable?
No, Eupraxia Pharmac (EPRX) reported a net income of -$28.2M in fiscal year 2023.
What is Eupraxia Pharmac's earnings per share (EPS)?
Eupraxia Pharmac (EPRX) reported diluted earnings per share of $-1.17 for fiscal year 2023. This represents a -21.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Eupraxia Pharmac's operating cash flow?
Eupraxia Pharmac (EPRX) generated -$20.7M in operating cash flow during fiscal year 2023, representing cash generated from core business activities.
What are Eupraxia Pharmac's total assets?
Eupraxia Pharmac (EPRX) had $20.3M in total assets as of fiscal year 2023, including both current and long-term assets.
How much does Eupraxia Pharmac spend on research and development?
Eupraxia Pharmac (EPRX) invested $20.6M in research and development during fiscal year 2023.
How many shares does Eupraxia Pharmac have outstanding?
Eupraxia Pharmac (EPRX) had 27M shares outstanding as of fiscal year 2023.
What is Eupraxia Pharmac's current ratio?
Eupraxia Pharmac (EPRX) had a current ratio of 1.02 as of fiscal year 2023, which is considered adequate.
What is Eupraxia Pharmac's debt-to-equity ratio?
Eupraxia Pharmac (EPRX) had a debt-to-equity ratio of 8.74 as of fiscal year 2023, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Eupraxia Pharmac's return on assets (ROA)?
Eupraxia Pharmac (EPRX) had a return on assets of -139.3% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.
What is Eupraxia Pharmac's cash runway?
Based on fiscal year 2023 data, Eupraxia Pharmac (EPRX) had $19.3M in cash against an annual operating cash burn of $20.7M. This gives an estimated cash runway of approximately 11 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Eupraxia Pharmac's Piotroski F-Score?
Eupraxia Pharmac (EPRX) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Eupraxia Pharmac's earnings high quality?
Eupraxia Pharmac (EPRX) has an earnings quality ratio of 0.73x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.